Bravis Ziekenhuis | Roosendaal - Cardiology Department

Research site

(Unclaimed)

Location

Boerhaavelaan 25, Roosendaal, Noord-Brabant, Netherlands

Site insights

Top conditions

Top treatments

Semaglutide

Atezolizumab

Ribociclib

Bevacizumab

Dapagliflozin

Olaparib

Fulvestrant

panitumumab

Panitumumab

Durvalumab

Parent organization

This site is a part of Bravis Ziekenhuis

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 32 total trials

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Investigator's Choice Chemotherapy

Biological: Epcoritamab

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1)

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 s...

Active, not recruiting

Obesity

Drug: Placebo cagrilintide

Drug: Cagrilintide

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Not yet enrolling

Acute Myocardial Infarction (AMI)

Cardiovascular Risk

Drug: Placebo

Drug: Ziltivekimab

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION)

Digoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the earl...

Active, not recruiting

Heart Failure

Drug: Digoxin

Drug: Placebos

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only

Acute Myocardial Infarction

Combination Product: Placebo

Combination Product: Selatogrel

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-30...

Active, not recruiting

Lymphoma, Mantle-Cell

Drug: Ibrutinib

Drug: Pirtobrutinib

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (NEOLBC)

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of rib...

Active, not recruiting

Breast Neoplasms

Drug: Chemotherapy

Drug: Letrozole

The Drug Rediscovery Protocol (DRUP Trial)

This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer d...

Enrolling

Tumors

Neoplasm

Drug: Tepotinib

Drug: Axitinib

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Rationale:Sodium glucose co transporter 2 (SGLT2) inhibitors are a relatively new class of agents, originally developed as oral antihyperglycemic dru...

Invitation-only

Kidney Failure

Death

Drug: Dapagliflozin 10 mg/day (oral)

Drug: Placebo

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular...

Active, not recruiting

Breast Cancer

Drug: Paclitaxel

Drug: Carbo/cyclo + atezolizumab

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)